Charter Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,034,850	53
2024	Research	$1,284,277	53
2023	Research	$1,579,573	42
2022	Research	$721,678	19
2021	Research	$765,298	22
2020	Research	$368,716	12

Breakdown

Who paid Research payments · program years 2020–2025

Eisai Inc. $4,428,044 148 payments
Roche Diagnostics Operations, Inc. $989,337 36 payments
BioXcel Therapeutics, Inc. $268,493 9 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $36,254 5 payments
Biogen, Inc. $31,241 1 payment
AbbVie, Inc. $1,022 2 payments

Studies the money was for Research payments · program years 2020–2025

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $2,901,319 82 payments
Rd006263 $989,337 36 payments
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $771,520 31 payments
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $640,105 23 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy Andsafety Study of PRN Dosing of Bxcl501 Over A 12 Week Treatment Period Insubjects With Agitation Associated With Dementia Who Require at Leastmoderate to Full Assistance With Activities of Daily Living $137,722 3 payments
A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid $115,100 12 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of Bxcl501 Over A 12 Week Period in Subjects With Agitation Associated With Dementia $72,166 4 payments
Evaluation of Bxcl501 Placebo Instructions for Use and Comprehension of Training for Caregivers and Participants With Agitation Associated With Alzheimers Dementia Participating in Studies Investigating At-Home Administration $58,605 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $31,294 2 payments
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $31,241 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.